Edwards originally predicted the Sapien 3 Ultra transcatheter aortic valve would hit the European market this quarter, but the company is now pushing that back to later in 2018 to wait for data from a small single-arm multicenter trial in intermediate-risk patients. In other TAVR news, long-term data supporting Medtronic's CoreValve line of TAVR systems was featured at the recent American College of Cardiology meeting.
Edwards Lifesciences Corp. has launched a 30-patient single-arm study of its next-generation Sapien 3 Ultra balloon-expandable transcatheter aortic valve system, which will push the expected European launch of the system to later in 2018.
In its Feb. 1 fourth-quarter 2017 earnings call, Edwards predicted that the Sapien 3 Ultra, which has a taller outer...